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Abstract 1 
 2 
Calcium intake has been associated with a lower risk of colorectal cancer. Calcium signaling 3 
may enhance T cell proliferation and differentiation, and contribute to T-cell mediated antitumor 4 
immunity. In this prospective cohort study, we investigated the association between calcium 5 
intake and colorectal cancer risk according to tumor immunity status to provide additional 6 
insights into the role of calcium in colorectal carcinogenesis. The densities of tumour-infiltrating 7 
T-cell subsets (CD3+, CD8+, CD45RO (PTPRC)+, or FOXP3+ cell) were assessed using 8 
immunohistochemical and computer-assisted image analysis in 736 cancer cases that 9 
developed among 136,249 individuals in two cohorts. Hazard ratios (HRs) and 95% confidence 10 
intervals (CIs) were calculated using Cox proportional hazards regression. Total calcium intake 11 
was associated with a multivariable HR of 0.55 (comparing ≥1200 vs. <600 mg/day, 95% CI, 12 
0.36–0.84; ptrend=0.002) for CD8
+ T-cell-low but not for CD8+ T-cell-high tumours (HR=1.02, 13 
95%CI, 0.67–1.55; ptrend=0.47). Similarly, the corresponding HRs (95 CIs) for calcium for low vs. 14 
high T-cell infiltrated tumours were 0.63 (0.42–0.94; ptrend=0.01) and 0.89 (0.58–1.35; ptrend=0.20) 15 
for CD3+; 0.58 (0.39–0.87; ptrend=0.006) and 1.04 (0.69–1.58; ptrend =0.54) for CD45RO
+; and 16 
0.56 (0.36–0.85; ptrend=0.006) and 1.10 (0.72–1.67; ptrend=0.47) for FOXP3
+, although the 17 
differences by subtypes defined by T cell density were not statistically significant. These 18 
potential differential associations generally appeared consistent regardless of sex, source of 19 
calcium intake, tumor location, and tumor microsatellite instability status. Our findings suggest a 20 
possible role of calcium in cancer immunoprevention via modulation of T cell function. 21 
 22 
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Cancer Research. 
on April 27, 2020. © 2019 American Association forcancerpreventionresearch.aacrjournals.org Downloaded from 
Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited. 
Author Manuscript Published OnlineFirst on February 13, 2019; DOI: 10.1158/1940-6207.CAPR-18-0279 
 7 / 29 
 
Introduction 1 
 2 
Research on calcium intake and colorectal neoplasia has important public health implications.  3 
Calcium is a simple, modifiable, inexpensive agent, and approximately 43% of U.S. adults use 4 
supplemental calcium (1).  Further, most epidemiological studies (2-4) have reported an inverse 5 
association between higher calcium intake and risk of developing colorectal adenoma and 6 
cancer.  However, evidence from the randomized controlled trials of calcium supplementation 7 
has been inconsistent (5,6).  Partly because of these discrepant findings, the Institute of 8 
Medicine called for more targeted research on calcium and colorectal cancer (7).  Most previous 9 
studies have investigated total colorectal cancer, but this tumor comprises a group of 10 
heterogeneous subtypes (8), and the association with calcium intake may therefore differ by 11 
specific molecular subtypes (9).  Hence, integrating host factors (such as diet) and tumor 12 
molecular features (such as immunity status) may enhance our understanding of the 13 
mechanisms through which calcium may act on colorectal carcinogenesis. 14 
 15 
Accumulating evidence suggests that effector or cytotoxic (CD3+ cells and CD8+ cells), memory 16 
[CD45RO (PTPRC)+ cells], and regulatory (FOXP3+ cells) T cells play an important role in 17 
colorectal cancer development and prognosis (10-12).  Calcium acts as second messenger in 18 
lymphocytes that enhances T cell proliferation and regulates its differentiation, and gene 19 
expression (13,14).  Hence, it is plausible that calcium may influence colorectal carcinogenesis 20 
through immunity.  In fact, human trials showed that supplementation with calcium could reduce 21 
several tumor-promoting inflammation biomarkers (15-17), and reverse the upregulation of 22 
expression of genes involved in inflammation and immune response induced by Western-style 23 
diet which is low in calcium (18).  In light of the biological evidence, we hypothesized that the 24 
association between calcium intake and colorectal cancer risk might differ by tumor immunity 25 
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status defined by densities of infiltrated T cells in the tumor microenvironment. 1 
 2 
To test this hypothesis, we conducted an immunologic molecular pathological epidemiology 3 
study (8) by integrating data on calcium intake, colorectal cancer outcomes, and tumor 4 
pathological immunity status from two large U.S.-nationwide prospective cohorts, the Nurses’ 5 
Health Study (NHS) and the Health Professionals Follow-up Study (HPFS).  We examined the 6 
association between calcium intake and risk of colorectal cancer according to the T cell 7 
densities in tumor tissue.  8 
 9 
Materials and Methods 10 
 11 
Study Population 12 
 13 
The study population included 121 700 female participants from NHS and 51 529 male 14 
participants from HPFS (19,20).  Briefly, for NHS, the recruitment of 121 700 U.S. female 15 
registered nurses aged 30 to 55 years was completed in 1976.  For HPFS, the recruitment of 51 16 
529 U.S. male professionals aged 40 to 75 years was completed in 1986.  In both cohorts, 17 
questionnaires were administrated biennially to collect and update information on demographic 18 
characteristics, lifestyle factors, and medical history, with follow-up rates over 90% in each 19 
cohort.  This study was approved by the institutional review boards of the Brigham and 20 
Women’s Hospital and Harvard T.H. Chan School of Public Health.  In this study, we excluded 21 
participants with a history of cancer (except for non-melanoma skin cancer), polyposis 22 
syndrome, ulcerative colitis/Crohn’s disease, implausible energy intakes at baseline (<600 23 
or >3500 kcal/day for women, or <800 or >4200 kcal/day for men), or with no reports of calcium 24 
intake.  After exclusion, a total of 136 249 participants (88 509 women and 47 740 men) were 25 
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included in the present analysis.  A flow chart showing how the study population for analysis 1 
was developed is presented in Supplementary Figure 1. 2 
 3 
Assessments of calcium intake and other dietary factors 4 
 5 
Details on assessments of calcium intake as well as other dietary factors were described 6 
previously (2,9,21).  In brief, we used validated (22,23) semi-quantitative food frequency 7 
questionnaires (FFQs) to collect dietary information at baseline and every 4 year thereafter.  8 
The energy-adjusted correlation coefficients of total calcium intake comparing the FFQs and the 9 
average of multiple 1-week diet records were 0.61 for men (22) and 0.63 for women (23).  The 10 
correlation coefficients for dietary calcium intake were 0.60 for men (22) and 0.70 for women 11 
(23).  We also collected information on dietary factors including intakes of alcohol, vitamin D, 12 
folate, red meat and processed meat (22,24). 13 
 14 
Assessments of covariates 15 
 16 
We collected information on potential colorectal cancer risk factors including height, adult body 17 
weight, physical activity (metabolic equivalent task score [METS]-hours/week), cigarette 18 
smoking, sigmoidoscopy/colonoscopy screening, family history of colorectal cancer, aspirin use, 19 
and menopausal status, and use of menopausal hormones on the baseline and updated in 20 
biennial follow-up questionnaires.  21 
 22 
Ascertainment of colorectal cancer cases 23 
 24 
The incident colorectal cancer cases were defined as a primary tumor with International 25 
Classification of Diseases-9 codes of 153 and 154.  Participants from the two cohorts were 26 
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asked for written permission to obtain medical records and pathological reports if they reported 1 
colorectal cancer on biennial questionnaires.  We searched state vital statistics records, the 2 
National Death Index, to identify additional unreported cancer deaths.  For all deaths attributable 3 
to colorectal cancer, we requested permission from next-of-kin to review medical records.  All 4 
possible cancer cases were further confirmed through review of medical and pathological 5 
records.  A study physician who was blinded to exposure data abstracted information on tumor 6 
anatomic location, stage, and histology type.  We included colon and rectal carcinoma cases 7 
based on the colorectal continuum model (25,26). 8 
 9 
Tumor immunity and molecular analyses 10 
We constructed tissue microarray (27), and assessed CD3+ cell, CD8+ cell, CD45RO (PTPRC)+ 11 
cell, and FOXP3+ cell densities in tumor tissue using immunohistochemistry.  We used image 12 
analysis through an automated scanning microscope and the Ariol image analysis system 13 
(Genetix, San Jose, California, USA) to calculate the average density (cells per mm2) of each T 14 
cell subset in tissue microarray cores, as previously reported (10).  We classified each of the T-15 
cell densities (cells per mm2) into quartiles (Q1–Q4) and divided cases into two groups: low 16 
(Q1–Q2) or high (Q3–Q4) in the analyses for statistical efficiency.  We also analyzed tumor 17 
microsatellite instability (MSI) status and calcium sensing receptor (CASR) expression as 18 
previously reported (9,28,29). DNA from paraffin-embedded tissue was extracted.  The status of 19 
MSI was determined by analyzing variability in the length of the microsatellite markers from 20 
tumor DNA compared to normal DNA, including D2S123, D5S346, D17S250, BAT25, BAT26, 21 
BAT40, D18S55, D18S56, D18S67, and D18S487 (29).  As previously described (9), we 22 
constructed tissue microarrays from colorectal cancer blocks, and conducted 23 
immunohistochemistry for CASR. CASR expression levels in all cases were reviewed by Y.M.  24 
For agreement study, selected tumors (n=118) were independently examined by a second 25 
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observer (Z.R.Q.), and the concordance between the two observers (Y.M. and Z.R.Q) was 1 
reasonable with a weighted κ of 0.71 (95% CI: 0.61–0.82) (9). 2 
 3 
Statistical analysis 4 
 5 
Age-adjusted and multivariable-adjusted cohort-specific hazard ratios (HRs) and 95% 6 
confidence intervals (CIs) for each colorectal cancer subtype according to the densities of 7 
tumor-infiltrated T-cell subsets (i.e., CD3+ cells, CD8+ cells, CD45RO+ cells, and FOXP3+ cells) 8 
were calculated using the duplication method Cox proportional hazards regression model (30).  9 
This method permits the estimation of separate regression coefficients for the exposure 10 
stratified by CRC subtype defined by the densities of tumor-infiltrated T-cell subsets (30). The 11 
model was stratified simultaneously by age (in months) and year of questionnaire return (every 12 
two year since baseline questionnaire), accounting for the finest possible control of confounding 13 
for age and secular trends.  Person-years of follow-up were calculated from the date of baseline 14 
questionnaire return to the date of diagnosis of colorectal cancer, date of death, loss to follow-15 
up, or the end of follow-up (June 1, 2012 for the NHS and January 31, 2012 for the HPFS), 16 
whichever came first.  Cancer cases without tumor immunity data were censored at diagnosis.  17 
We used the energy-adjusted(31) cumulative average intake of total calcium as reported on all 18 
available questionnaires up to the start of each 4-year follow-up interval as the main exposure 19 
(2), to minimize within-person variation and to better reflect long-term intake.  Likewise, we used 20 
cumulative average for covariates and modeled them as time-varying variables when 21 
appropriate to allow for potential changes over follow-up periods.  The adjusted covariates as 22 
well as their categorizations in the multivariable models were shown in Table 1 and Table 2 23 
footnotes.  We found no violation of proportional hazard assumption.  24 
 25 
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Our primary hypothesis testing was the heterogeneity test on the subtype-specific associations 1 
(statistical linear trends) of calcium intake with risk of colorectal cancer subtypes classified by 2 
densities of tumor-infiltrating T-cells.  Considering multiple hypothesis testing for our four 3 
primary hypotheses associated with 4 immunity variables (i.e., densities of CD3+ cells, CD8+ 4 
cells, CD45RO+ cells, and FOXP3+ cells), we adjusted α level to 0.01 (≈0.05/4) by Bonferroni 5 
correction.  All other analyses including evaluations of individual HRs and evaluations of a 6 
statistical linear trend in a specific stratum represent secondary analyses.  We examined the 7 
statistical significance of the differences in association according to cancer subtypes using the 8 
likelihood ratio test that compared the model fit that allowed separate associations by different 9 
tumor immunity status with the model fit that assumed a common effect (30).  Trend tests were 10 
conducted using the median of each category of total calcium intake as a continuous variable.  11 
To maximize statistical power, we combined the results from the two cohorts since we did not 12 
observe any significant heterogeneity between sex (pheterogeneity for sex=0.16).  13 
 14 
In secondary analyses, we examined the associations between calcium intake and colorectal 15 
cancer risk according to the densities of tumor-infiltrated T cells by sex, tumor location, and 16 
source of calcium intake.  We also explored a time-lagged analysis (2) using 8-year time latency.  17 
To account for potential confounding by tumor MSI status, we further evaluated these 18 
associations jointly by tumor-infiltrated T cells and MSI status.  Lastly, we assessed the 19 
associations stratified by tumor CASR status because we speculated that CASR may partially 20 
mediate the potential effect of calcium on colorectal cancer immunoprevention (9).  All analyses 21 
were performed using the SAS software (SAS Institute, Version 9.2, Cary, NC). 22 
 23 
Results 24 
 25 
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During up to 32 years of follow-up of 136 249 participants (88 509 women and 47 740 men) in 1 
these prospective cohorts, we identified 3079 colorectal adenocarcinoma cases.  Among cases 2 
with available tissue specimens, we could assess T-cell infiltration in the tumor 3 
microenvironment for 736 cases (472 women and 264 men).  The included colorectal cancer 4 
cases with immunity data were comparable to all eligible colorectal cancer patients without 5 
immunity data (Supplementary Table 1).  Participants with lower total calcium intake were more 6 
likely to be current smokers, consumed more alcohol, and tended to have higher intake of red 7 
meat, processed meat, and fat, but less vitamin D and folate (Table 1).  8 
 9 
As shown in Table 2, we found that higher calcium intake appeared to be associated with a 10 
lower risk of colorectal carcinomas containing low densities of CD8+ cells (ptrend=0.002) but not 11 
with risk of carcinoma containing high densities of CD8+ cells (ptrend=0.47), although the 12 
difference was not statistically significant (pheterogeneity=0.06, with the adjusted α of 0.01 by 13 
Bonferroni correction).  Specifically, compared to calcium intake of <600 mg/day, calcium intake 14 
of ≥1200 mg/day was associated with a multivariable HR of 0.55 (95% CI, 0.36–0.84) for CD8+ 15 
T-cell-low tumors and of 1.02 (95% CI, 0.67–1.55) for CD8+ T-cell-high tumors. Similarly, the 16 
corresponding HRs (95 CIs) for low vs. high T-cell tumours were 0.63 (0.42–0.94; ptrend =0.01) 17 
and 0.89 (0.58–1.35; ptrend=0.20) for CD3
+  (pheterogeneity=0.30); 0.58 (0.39–0.87; ptrend=0.006) and 18 
1.04 (0.69–1.58; ptrend =0.54) for CD45RO
+ (pheterogeneity=0.09); and 0.56 (0.36–0.85; ptrend=0.006) 19 
and 1.10 (0.72–1.67; ptrend=0.47) for FOXP3
+  (pheterogeneity=0.04),although the differences by 20 
subtypes defined by T cell density were not statistically significant for any of the T cells 21 
examined. 22 
 23 
Though statistical power was generally limited, the stronger inverse associations of calcium 24 
intake with tumours infiltrated with low densities of T cells but not high generally appeared 25 
consistent regardless of sex (Supplementary Table 2 and Supplementary Table 3), source of 26 
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calcium intake (Table 3), tumor location (Supplementary Table 4), tumor MSI status 1 
(Supplementary Table 5), and time-lagged analyses (Supplementary Table 6).  Interestingly, the 2 
potential differential associations appeared slightly stronger in CASR positive tumors 3 
(Supplementary Table 7).  4 
 5 
Discussion 6 
 7 
In these two large prospective cohort studies, we found that higher calcium intake appeared to 8 
be primarily associated with lower risk of colorectal cancer infiltrated with low, but not high, 9 
densities of T cells regardless of the type of T cell examined, although the differences in the 10 
associations by subtype were not statistically significant for any of the T cells examined.  These 11 
suggestive differential associations generally persisted regardless of sex, source of calcium 12 
intake, tumor location, and tumor microsatellite instability status.  Our findings suggest a 13 
possible role of calcium in colorectal cancer immunoprevention (32) through modulation of T 14 
cells. 15 
 16 
The role of immunity in cancer development and progression is becoming increasingly 17 
recognized (33-36).  In this study, we investigated whether the potential anti-cancer effect of 18 
calcium on colorectal cancer differs by immune status in the tumor microenvironment.  The 19 
observed differential associations by tumor immunity status suggest potential crosstalk between 20 
calcium intake and host immunity in affecting colorectal carcinogenesis.  In the immune system, 21 
calcium is essential for diverse cellular functions including proliferation, differentiation, and 22 
effector function (37).  Changes in the flux of calcium ions (Ca2+) through Ca2+ channels in 23 
lymphocyte membranes play an important role in the regulation of T cell function and immunity 24 
(13,14,38).  Of note, dysregulated Ca2+ responses are critical for T cell-mediated autoimmunity 25 
and inflammation including inflammatory bowel disease (38,39), a risk factor for colorectal 26 
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cancer (15).   In line with experimental studies showing a potential effect of calcium on immunity, 1 
clinical trials have shown that supplementation with calcium reduces several tumor-promoting 2 
inflammation biomarkers (15-17).  Furthermore, a recent human crossover trial (18) showed that 3 
consumption of a Western-style diet (characterized by low calcium and vitamin D) modestly 4 
upregulated genes (e.g., human leukocyte antigen class genes) which are involved in 5 
inflammation and immune response.  In contrast, supplementation of calcium (but not vitamin D) 6 
to Western-style diet reversed these deleterious effects, and upregulated genes in the anti-7 
inflammatory interferon signaling and the IL23 pathways (18). 8 
 9 
It is also possible that calcium exerts its immunomodulatory effect partially via CASR.  The 10 
CASR, a calcium-binding G protein-coupled receptor, is expressed in the entire intestinal 11 
epithelium and plays a key role in the preservation of gut microbiota and immune homeostasis 12 
(40-42).  The CASR is also functionally expressed in human T lymphocytes (43).   Evidence 13 
shows that intestinal epithelial CASR deficiency enhances permeability of the epithelial barrier, 14 
leading to the translocation and dissemination of luminal bacteria and activation of local and 15 
systemic innate and adaptive proinflammatory immune responses (44).  In addition, calcium 16 
may promote T lymphocyte function through activation of CASR to secrete cytokines including 17 
IL6 and LTA (TNF-β) (43), which may play important roles in immune defense as well as 18 
systemic inflammatory response.  Collectively, our data support that calcium exerts its 19 
immunomodulatory effect partially via CASR as the differential associations we observed by 20 
immunity status appeared slightly stronger in CASR-positive tumors than in CASR-negative 21 
tumors (see Supplementary Table 7).  However, the exact mechanisms underlying these 22 
differential associations remain unclear.  We emphasize that our study remains hypothesis 23 
generating and requires confirmation from independent studies.  24 
 25 
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Our study also suggests a different role of host immunity in mediating the effect of calcium and 1 
vitamin D in colorectal cancer chemoprevention because we previously found that the inverse 2 
association for plasma 25(OH)D was stronger for risk of colorectal cancer subtypes with intense 3 
immune reactions (35).  Consistently, the aforementioned human crossover trial found that 4 
supplementing the Western-style diet with 1,25(OH)2D3 upregulated genes involved in immune 5 
response and inflammation pathways, whereas calcium supplementation largely abrogated 6 
these changes (18). 7 
 8 
Recent studies showed that MSI-high colorectal cancers were sensitive to immune checkpoint 9 
blockade (45,46), indicating an important interplay between MSI status and immune cells.  MSI-10 
high tumors have frame shift mutations in coding sequences throughout the genome, which may 11 
elicit intense and more diverse immune responses and improve cancer survival (47,48).  In the 12 
current study, however, the observed differential associations appeared to be independent of 13 
MSI status.  This suggests that MSI status is not the sole determinant of tumor immune 14 
response since the levels of T cell infiltrates overlap considerably between MSI-high and non-15 
MSI-high tumors, though are on average higher in MSI-high cancers (10). 16 
 17 
Our present study has several strengths, including prospective cohort design, high follow-up 18 
rates, validated colorectal cancer outcomes, and the use of repeated measures of calcium and 19 
other covariates during follow-up of the cohorts.  The integration of tumor immunology analyses 20 
into the framework of molecular pathological epidemiology is an emerging research area 21 
(49)(50), which enabled us to better understand etiological heterogeneity according to tumor 22 
molecular and immune features.  However, several limitations should be noted.  First, despite 23 
the overall large sample size of the cohorts, we had a limited number of cases with tumor tissue 24 
data on T cell infiltration for the secondary analyses by anatomic subsites, sources of calcium 25 
intake, tumor MSI or CASR status.  Second, the inclusion of cancer cases with available tissue 26 
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specimen may introduce potential selection bias.  However, cases that provided tumor tissue 1 
were comparable to all eligible cases with regard to a number of demographic, dietary and 2 
lifestyle factors.  Third, because most of participants in our study are Caucasian U.S. health 3 
professionals, the generalizability of our findings to the general population is limited.  However, 4 
little heterogeneity across diverse populations has been suggested in the association between 5 
calcium intake and risks of colorectal cancer (3).  Lastly, we cannot rule out residual 6 
confounding although we have adjusted for a wide range of known risk factors for colorectal 7 
cancer. 8 
 9 
In summary, we found inverse associations between calcium intake and risk of colorectal 10 
cancers with low densities of T cell infiltration, but not with risk of colorectal cancers with high 11 
densities of T cell infiltration, although the differences by subtypes defined by T cell density 12 
were not statistically significant for any of the T cells examined.  Our results suggest a possible 13 
immunomodulatory effect of calcium in colorectal carcinogenesis.  Future studies are warranted 14 
to confirm our findings and elucidate the underlying mechanisms for colorectal cancer 15 
immunoprevention by calcium. 16 
  17 
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Table 1. Baseline characteristics of participants by frequency of total calcium intake in the Nurses’ Health Study (1980) and 
Health Professionals Follow-up Study (1986) 
 Total calcium intake (mg/d) 
 <600  600-799  800-999  1000-1199 ≥1200 
Women (Nurses’ Health Study)     
No. 34,137 24,290 14,732 8,325 7,022 
Age, years* 46.5(7.0) 46.8(7.2) 46.8(7.3) 46.7(7.4) 47.1(7.4) 
White, % 96.4 98.0 98.3 98.4 98.2 
Body mass index, kg/m² 24.0(4.2) 24.0(4.2) 24.1(4.1) 24.2(4.1) 24.4(4.4) 
Activity, METS-hours/week 12.5(18.0) 14.2(19.7) 15.2(21.5) 15.3(21.0) 16.2(26.4) 
Family history of colorectal cancer, % 7.9 7.8 7.9 7.9 7.7 
Regular aspirin use (2 or more tablets/week), % 33.1 33.4 32.7 31.4 30.6 
Past smoking, % 25.3 28.8 29.2 28.9 28.5 
Current smoking, % 32.0 27.5 26.4 26.0 26.1 
Multivitamin use, % 28.5 33.8 37.9 40.6 45.0 
History of sigmoidoscopy/endoscopy, % 9.9 10.0 10.0 10.6 10.4 
Postmenopausal status, % 45.0 44.0 44.2 43.9 44.8 
Postmenopausal hormone use, % 18.3 18.5 18.8 19.3 19.2 
Total energy intake, kcal/day 1573(513) 1546(484) 1565(518) 1602(481) 1569(497) 
Dietary calcium intake, mg/day 457(97) 691(61) 883(71) 1078(88) 1376(263) 
Dairy calcium intake, mg/day 211(94) 413(97) 595(113) 791(132) 1082(287) 
Supplemental calcium intake**, mg/day 358(434) 372(426) 382(424) 392(433) 402(456) 
Alcohol, g/day 7.8(12.5) 6.2(9.6) 5.5(8.8) 4.8(8.1) 3.9(7.2) 
Total folate intake, μg/day 311(228) 365(236) 399(253) 417.2(262) 503(504) 
Total vitamin D, IU/day 238(227) 309(238) 378(252) 451(268) 606(489) 
Red meat, servings/week 3.2(2.3) 2.4(1.8) 2.1(1.7) 1.9(1.5) 1.5(1.4) 
Processed meat, servings/week 1.3(1.9) 1.2(1.8) 1.0(1.6) 0.9(1.6) 0.7(1.2) 
Total fat, g/day 73.6(14.3) 69.9(12.6) 66.9(12.8) 64.9(12.8) 61.9(13.6) 
Total fiber, g/day 15.4(5.6) 17.4(6.2) 18.1(6.9) 17.9(6.9) 17.6(7.4) 
ω-3 polyunsaturated fatty acids, g/day 0.2(0.1) 0.2(0.2) 0.2(0.2) 0.2(0.2) 0.2(0.2) 
ω-6 polyunsaturated fatty acids, g/day 6.4(2.5) 6.3(2.4) 6.1(2.4) 6.0(2.4) 5.9(2.6) 
Men (Health Professional Follow-up study)     
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No. 10,817 13,820 9,049 5,328 8,726 
Age, years* 54.0(9.6) 53.9(9.7) 54.5(9.9) 54.6(9.9) 55.8(9.8) 
White, % 93.3 95.8 96.7 97.0 97.3 
Body mass index, kg/m² 25.6(3.4) 25.6(3.3) 25.5(3.2) 25.4(3.3) 25.4(3.3) 
Activity, METS-hours/week 18.3(27.3) 20.8(28.5) 22.3(31.7) 21.8(31.5) 22.6(30.5) 
Family history of colorectal cancer, % 8.7 8.3 8.3 8.6 8.5 
Regular aspirin use (2 or more tablets/week), % 26.9 28.9 30.1 31.0 31.3 
Past smoking, % 43.5 42.9 40.9 40.5 39.6 
Current smoking, % 12.4 9.7 8.2 8.9 8.1 
Multivitamin use, % 50.6 57.5 62.0 67.3 74.2 
History of sigmoidoscopy/endoscopy, % 24.0 26.2 26.9 26.7 27.1 
Total energy intake, kcal/day 1957(638) 1994(605) 1956(632) 2111(631) 1959(583) 
Dietary calcium intake, mg/day 500(76) 683(78) 845(115) 982(109) 1180(395) 
Dairy calcium intake, mg/day 201(76) 357(98) 506(136) 643(206) 838(409) 
Supplemental calcium intake, mg/day 7(22) 21(55) 52(103) 118(180) 423(550) 
Alcohol, g/day 15.5(19.3) 11.8(14.9) 9.6(13.3) 9.9(14.2) 8.2(12.1) 
Total folate intake, μg/day 381(210) 447(227) 497(251) 529(287) 612(363) 
Total vitamin D, IU/day 272(241) 338(253) 407(279) 488(291) 637(371) 
Red meat, servings/week 2.2(1.9) 1.9(1.6) 1.6(1.5) 1.7(1.5) 1.4(1.4) 
Processed meat, servings/week 1.4(2.0) 1.3(1.8) 1.1(1.8) 1.2(1.9) 1.0(1.7) 
Total fat, g/day 73.5(14.6) 72.2(13.3) 70.2(13.7) 70.6(13.8) 68.6(14.5) 
Total fiber, g/day 19.1(6.4) 21.1(6.5) 22.3(7.1) 21.6(7.6) 21.8(7.9) 
ω-3 polyunsaturated fatty acids, g/day 0.3(0.3) 0.3(0.3) 0.3(0.3) 0.3(0.3) 0.3(0.2) 
ω-6 polyunsaturated fatty acids, g/day 12.2(3.8) 12.0(3.5) 11.6(3.4) 11.5(3.4) 10.9(3.4) 
Values are means (SD) or percentages and are standardized to the age distribution of the study population. 
* Value is not age adjusted. 
    ** Calcium supplement data of NHS were based on questionnaires returned in 1986. 
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Table 2. Total calcium intake and risk of colorectal cancer according to densities of tumor-infiltrating T-cell subsets in the 
Nurses’ Health Study (1980-2012) and Health Professionals Follow-up Study (1986-2012) 
 Total calcium intake (mg/d)  
 <600  600-799  800-999  1000-1199 ≥1200 ptrend* pheterogeneity¶ 
Total colorectal cancer       
Person-years (n=3,663,039) 617,339 889,849 809,364 596,191 750,297   
No. cases (n=736) 116 207 176 121 116   
Age-adjusted HR (95% CI) 1 (ref) 1.10 (0.87-1.38) 1.00 (0.79-1.27) 0.94 (0.72-1.21) 0.68 (0.53-0.89) 0.0002  
Multivariable HR (95%CI) § 1 (ref) 1.12 (0.89-1.42) 1.04 (0.80-1.34) 1.01 (0.76-1.34) 0.80 (0.60-1.08) 0.04  
CD3
+
      
Low        
No. cases (n=347) 64 103 73 58 49   
Age-adjusted HR (95% CI) 1 (ref) 1.01 (0.74-1.39) 0.78 (0.56-1.10) 0.85 (0.59-1.22) 0.55 (0.38-0.80) 0.0004 0.34 
Multivariable HR (95% CI)§ 1 (ref) 1.02 (0.74-1.40) 0.80 (0.56-1.14) 0.89 (0.61-1.31) 0.63 (0.42-0.94) 0.01 0.30 
High        
No. cases (n=350) 48 98 91 56 57   
Age-adjusted HR (95% CI) 1 (ref) 1.22 (0.86-1.73) 1.20 (0.84-1.71) 1.00 (0.67-1.48) 0.76 (0.52-1.13) 0.03  
Multivariable  HR (95% CI)§ 1 (ref) 1.24 (0.88-1.77) 1.24 (0.86-1.78) 1.07 (0.71-1.61) 0.89 (0.58-1.35) 0.20  
CD8
+
      
Low        
No. cases (n=339) 59 93 86 55 46   
Age-adjusted HR (95% CI) 1 (ref) 0.95 (0.68-1.32) 0.91 (0.65-1.27) 0.77 (0.53-1.11) 0.48 (0.33-0.72) <0.0001 0.06 
Multivariable  HR (95% CI)§ 1 (ref) 0.95 (0.68-1.33) 0.92 (0.65-1.30) 0.80 (0.54-1.18) 0.55 (0.36-0.84) 0.002 0.06 
High        
No. cases (n=344) 47 104 79 57 57   
Age-adjusted HR (95% CI) 1 (ref) 1.38 (0.97-1.95) 1.16 (0.80-1.67) 1.17 (0.79-1.74) 0.90 (0.60-1.33) 0.14  
Multivariable  HR (95% CI)§ 1 (ref) 1.40 (0.98-1.98) 1.18 (0.81-1.72) 1.24 (0.82-1.87) 1.02 (0.67-1.55) 0.47  
CD45RO
+
      
Low        
No. cases (n=348) 65 98 80 57 48   
Age-adjusted HR (95% CI) 1 (ref) 0.91 (0.66-1.24) 0.81 (0.58-1.13) 0.79 (0.55-1.13) 0.50 (0.35-0.74) 0.0002 0.11 
Multivariable  HR (95% CI)§ 1 (ref) 0.92 (0.67-1.27) 0.84 (0.59-1.18) 0.84 (0.57-1.23) 0.58 (0.39-0.87) 0.006 0.09 
High        
No. cases (n=359) 47 101 89 60 62   
Age-adjusted HR (95% CI) 1 (ref) 1.35 (0.96-1.92) 1.25 (0.87-1.79) 1.14 (0.77-1.68) 0.89 (0.61-1.31) 0.12  
Multivariable  HR (95% CI)§ 1 (ref) 1.38 (0.97-1.96) 1.29 (0.89-1.86) 1.22 (0.81-1.82) 1.04 (0.69-1.58) 0.54  
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FOXP3
+
      
Low        
No. cases (n=336) 61 89 89 55 42   
Age-adjusted HR (95% CI) 1 (ref) 0.91 (0.65-1.26) 0.98 (0.70-1.36) 0.81 (0.56-1.17) 0.47 (0.32-0.71) 0.0001 0.04 
Multivariable  HR (95% CI)§ 1 (ref) 0.92 (0.66-1.29) 1.01 (0.72-1.43) 0.87 (0.59-1.28) 0.56 (0.36-0.85) 0.006 0.04 
High        
No. cases (n=337) 45 95 74 59 64   
Age-adjusted HR (95% CI) 1 (ref) 1.30 (0.91-1.85) 1.05 (0.72-1.53) 1.16 (0.78-1.72) 0.94 (0.64-1.39) 0.29  
Multivariable  HR (95% CI)§ 1 (ref) 1.32 (0.92-1.89) 1.07 (0.73-1.59) 1.23 (0.81-1.86) 1.10 (0.72-1.67) 0.87  
CI, confidence interval; HR, hazard ratio. 
Duplication-method Cox proportional cause-specific hazards regression for competing risks data was used to compute HRs and 95% CIs. 
All analyses were stratified by age (in month), year of questionnaire return and sex.   
*: Linear trend test using the median intake of each category. 
¶: The likelihood ratio test was used to test for the heterogeneity of the association between total calcium intake and colorectal cancer risk by 
densities of tumor-infiltrating T-cell subsets. 
§: Multivariable hazard ratios were adjusted for age (in month), race (Caucasian vs. non-Caucasian), adult BMI (< 25, 25 -< 27.5, 27.5 -< 30, or ≥ 
30 kg/m
2
), smoking (0, 1-10, or > 10 pack-years), history of colorectal cancer in a parent or sibling (yes or no), history of 
sigmoidoscopy/colonoscopy (yes or no), physical activity (< 3, 3-< 27, ≥ 27 MET-hrs/wk), regular aspirin use (yes, no), alcohol 
consumption (0 -< 5, 5 -< 15, or ≥ 15 g/d), energy-adjusted total intake of folate, vitamin D, red meat and processed meat (all in tertiles).  
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Table 3. Intake of dietary calcium, dairy calcium and calcium supplement and risk of colorectal cancer according to 
densities of tumor-infiltrating T-cell subsets in the Nurses’ Health Study (1980-2012) and Health Professionals Follow-up 
Study (1986-2012) 
 Dietary calcium intake (mg/d)   
 <600  600-749  750-899  ≥900 ptrend* pheterogeneity¶ 
Total colorectal cancer      
Person-years (n=3,663,039) 1,006,115 1,018,393 769,809 868,723   
No. cases (n=736) 205 210 160 161   
Age-adjusted HR (95% CI) 1 (ref) 0.97 (0.80-1.17) 0.98 (0.79-1.20) 0.86 (0.69-1.05) 0.15  
Multivariable HR (95%CI) § 1 (ref) 1.00 (0.82-1.23) 1.04 (0.83-1.30) 0.96 (0.76-1.21) 0.74  
CD3
+
     
Low       
No. cases (n=347) 110 97 62 78   
Age-adjusted HR (95% CI) 1 (ref) 0.84 (0.64-1.11) 0.74 (0.54-1.01) 0.80 (0.60-1.08) 0.12 0.78 
Multivariable  HR (95% CI)§ 1 (ref) 0.87 (0.66-1.15) 0.77 (0.56-1.06) 0.88 (0.64-1.20) 0.36 0.74 
High       
No. cases (n=350) 90 102 87 71   
Age-adjusted HR (95% CI) 1 (ref) 1.05 (0.79-1.39) 1.16 (0.86-1.56) 0.82 (0.60-1.12) 0.25  
Multivariable  HR (95% CI)§ 1 (ref) 1.08 (0.81-1.45) 1.23 (0.90-1.67) 0.90 (0.65-1.26) 0.63  
CD8
+
     
Low       
No. cases (n=339) 101 100 72 66   
Age-adjusted HR (95% CI) 1 (ref) 0.94 (0.71-1.25) 0.91 (0.67-1.23) 0.74 (0.54-1.01) 0.06 0.36 
Multivariable  HR (95% CI)§ 1 (ref) 0.97 (0.73-1.28) 0.94 (0.69-1.29) 0.80 (0.58-1.12) 0.20 0.36 
High       
No. cases (n=344) 91 98 77 78   
Age-adjusted HR (95% CI) 1 (ref) 1.01 (0.76-1.35) 1.05 (0.77-1.43) 0.91 (0.67-1.24) 0.53  
Multivariable  HR (95% CI)§ 1 (ref) 1.04 (0.78-1.39) 1.10 (0.80-1.51) 0.99 (0.71-1.37) 0.93  
CD45RO
+
     
Low       
No. cases (n=348) 106 94 66 82   
Age-adjusted HR (95% CI) 1 (ref) 0.82 (0.62-1.09) 0.77 (0.56-1.05) 0.81 (0.60-1.09) 0.18 0.62 
Multivariable  HR (95% CI)§ 1 (ref) 0.85 (0.64-1.13) 0.82 (0.59-1.12) 0.90 (0.66-1.23) 0.52 0.57 
High       
No. cases (n=359) 93 108 83 75   
Age-adjusted HR (95% CI) 1 (ref) 1.11 (0.84-1.47) 1.13 (0.84-1.52) 0.91 (0.67-1.24) 0.51  
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Multivariable  HR (95% CI)§ 1 (ref) 1.15 (0.87-1.53) 1.20 (0.88-1.64) 1.03 (0.74-1.42) 0.91  
FOXP3
+
     
Low       
No. cases (n=336) 104 89 62 81   
Age-adjusted HR (95% CI) 1 (ref) 0.81 (0.61-1.08) 0.75 (0.55-1.04) 0.84 (0.62-1.12) 0.22 0.57 
Multivariable  HR (95% CI)§ 1 (ref) 0.85 (0.64-1.14) 0.81 (0.59-1.12) 0.94 (0.68-1.28) 0.64 0.59 
High       
No. cases (n=337) 82 102 85 68   
Age-adjusted HR (95% CI) 1 (ref) 1.18 (0.88-1.58) 1.30 (0.95-1.76) 0.93 (0.67-1.28) 0.68  
Multivariable  HR (95% CI)§ 1 (ref) 1.23 (0.91-1.65) 1.38 (1.01-1.90) 1.03 (0.73-1.45) 0.82  
       
 Dairy calcium intake (mg/d)   
 0-299  300-499 500-699  ≥700   
Total colorectal cancer      
Person-years (n=3,663,039) 1,045,066 1,372,061 749,951 495,962   
Cases, No. (n=736) 223 266 149 98   
Age-adjusted HR (95% CI) 1 (ref) 0.90 (0.75-1.07) 0.90 (0.73-1.11) 0.87 (0.69-1.11) 0.25  
Multivariable HR (95%CI) § 1 (ref) 0.92 (0.76-1.10) 0.95 (0.76-1.19) 0.97 (0.75-1.26) 0.83  
CD3
+
     
Low       
No. cases (n=347) 111 126 64 46   
Age-adjusted HR (95% CI) 1 (ref) 0.87 (0.67-1.12) 0.80 (0.59-1.09) 0.84 (0.59-1.19) 0.24 0.99 
Multivariable  HR (95% CI)§ 1 (ref) 0.88 (0.68-1.14) 0.84 (0.61-1.15) 0.92 (0.64-1.32) 0.52 0.98 
High       
No. cases (n=350) 107 124 76 43   
Age-adjusted HR (95% CI) 1 (ref) 0.86 (0.66-1.11) 0.93 (0.70-1.26) 0.78 (0.55-1.11) 0.24  
Multivariable  HR (95% CI)§ 1 (ref) 0.88 (0.68-1.14) 0.98 (0.72-1.33) 0.86 (0.59-1.25) 0.54  
CD8
+
     
Low       
No. cases (n=339) 100 131 71 37   
Age-adjusted HR (95% CI) 1 (ref) 0.99 (0.76-1.28) 0.95 (0.70-1.29) 0.76 (0.52-1.10) 0.17 0.61 
Multivariable  HR (95% CI)§ 1 (ref) 1.00 (0.77-1.30) 0.99 (0.72-1.36) 0.82 (0.55-1.23) 0.40 0.62 
High       
No. cases (n=344) 109 118 66 51   
Age-adjusted HR (95% CI) 1 (ref) 0.81 (0.62-1.05) 0.82 (0.60-1.12) 0.91 (0.65-1.28) 0.50  
Multivariable  HR (95% CI)§ 1 (ref) 0.83 (0.63-1.08) 0.85 (0.62-1.17) 1.00 (0.70-1.42) 0.84  
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CD45RO
+
     
Low       
No. cases (n=348) 113 119 67 49   
Age-adjusted HR (95% CI) 1 (ref) 0.81 (0.62-1.05) 0.81 (0.60-1.10) 0.86 (0.61-1.21) 0.35 0.80 
Multivariable  HR (95% CI)§ 1 (ref) 0.82 (0.63-1.07) 0.85 (0.62-1.16) 0.95 (0.66-1.35) 0.71 0.72 
High       
No. cases (n=359) 104 132 77 46   
Age-adjusted HR (95% CI) 1 (ref) 0.93 (0.72-1.21) 0.99 (0.74-1.33) 0.88 (0.62-1.25) 0.56  
Multivariable  HR (95% CI)§ 1 (ref) 0.96 (0.74-1.25) 1.05 (0.77-1.43) 0.99 (0.69-1.44) 0.92  
FOXP3
+
     
Low        
No. cases (n=336) 114 114 66 42   
Age-adjusted HR (95% CI) 1 (ref) 0.75 (0.58-0.98) 0.78 (0.58-1.06) 0.72 (0.50-1.02) 0.06 0.05 
Multivariable  HR (95% CI)§ 1 (ref) 0.77 (0.59-1.01) 0.83 0.61-1.14) 0.79 (0.54-1.15) 0.21 0.05 
High       
No. cases (n=337) 85 130 74 48   
Age-adjusted HR (95% CI) 1 (ref) 1.15 (0.87-1.51) 1.17 (0.85-1.60) 1.15 (0.80-1.64) 0.41  
Multivariable  HR (95% CI)§ 1 (ref) 1.18 (0.89-1.55) 1.22 (0.88-1.69) 1.27 (0.88-1.86) 0.19  
       
 Calcium supplement (mg/d)   
 0-199  200-299 300-499 ≥500   
Total colorectal cancer      
Person-years (n=3,663,039) 2,505,441 321,408 428,893 407,297   
No. cases (n=736) 514 80 91 51   
Age-adjusted HR (95% CI) 1 (ref) 1.14 (0.89-1.45) 0.99 (0.78-1.25) 0.56 (0.42-0.75) 0.001  
Multivariable HR (95%CI) § 1 (ref) 1.22 (0.95-1.56) 1.10 (0.87-1.39) 0.67 (0.49-0.90) 0.09  
CD3
+
     
Low       
No. cases (n=347) 251 32 41 23   
Age-adjusted HR (95% CI) 1 (ref) 0.93 (0.64-1.36) 0.93 (0.66-1.30) 0.52 (0.34-0.80) 0.006 0.52 
Multivariable  HR (95% CI)§ 1 (ref) 0.99 (0.68-1.45) 1.03 (0.73-1.46) 0.62 (0.40-0.96) 0.07 0.49 
High       
No. cases (n=350) 237 43 48 22   
Age-adjusted HR (95% CI) 1 (ref) 1.32 (0.94-1.84) 1.12 (0.81-1.55) 0.51 (0.33-0.80) 0.05  
Multivariable  HR (95% CI)§ 1 (ref) 1.43 (1.02-2.00) 1.25 (0.90-1.74) 0.62 (0.39-0.97) 0.37  
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CD8
+
     
Low       
No. cases (n=339) 233 39 47 20   
Age-adjusted HR (95% CI) 1 (ref) 1.09 (0.77-1.54) 0.99 (0.72-1.37) 0.43 (0.27-0.68) 0.003 0.39 
Multivariable  HR (95% CI)§ 1 (ref) 1.16 (0.82-1.65) 1.10 (0.79-1.53) 0.51 (0.32-0.81) 0.05 0.38 
High       
No. cases (n=344) 244 37 39 24   
Age-adjusted HR (95% CI) 1 (ref) 1.21 (0.85-1.72) 0.99 (0.70-1.41) 0.61 (0.40-0.94) 0.07  
Multivariable  HR (95% CI)§ 1 (ref) 1.30 (0.91-1.86) 1.10 (0.77-1.57) 0.73 (0.47-1.13) 0.42  
CD45RO
+
     
Low       
No. cases (n=348) 258 34 37 19   
Age-adjusted HR (95% CI) 1 (ref) 1.01 (0.70-1.46) 0.85 (0.60-1.22) 0.43 (0.27-0.69) 0.0008 0.12 
Multivariable  HR (95% CI)§ 1 (ref) 1.08 (0.75-1.56) 0.94 (0.65-1.34) 0.51 (0.31-0.82) 0.01 0.11 
High       
No. cases (n=359) 237 44 49 29   
Age-adjusted HR (95% CI) 1 (ref) 1.27 (0.92-1.78) 1.07 (0.78-1.48) 0.65 (0.44-0.97) 0.15  
Multivariable  HR (95% CI)§ 1 (ref) 1.36 (0.97-1.90) 1.19 (0.86-1.65) 0.77 (0.52-1.16) 0.67  
FOXP3
+
     
Low        
No. cases (n=336) 238 35 41 22   
Age-adjusted HR (95% CI) 1 (ref) 1.09 (0.76-1.57) 0.96 (0.68-1.36) 0.53 (0.34-0.82) 0.01 0.63 
Multivariable  HR (95% CI)§ 1 (ref) 1.18 (0.82-1.70) 1.08 (0.76-1.53) 0.63 (0.40-1.00) 0.15 0.64 
High       
No. cases (n=337) 226 44 42 25   
Age-adjusted HR (95% CI) 1 (ref) 1.35 (0.97-1.88) 0.99 (0.70-1.39) 0.59 (0.39-0.90) 0.06  
Multivariable  HR (95% CI)§ 1 (ref) 1.44 (1.03-2.02) 1.10 (0.78-1.55) 0.71 (0.46-1.09) 0.41  
CI, confidence interval; HR, hazard ratio. 
Duplication-method Cox proportional cause-specific hazards regression for competing risks data was used to compute HRs and 95% CIs. 
All analyses were stratified by age (in month), year of questionnaire return and sex.   
*: Linear trend test using the median intake of each category. 
¶: The likelihood ratio test was used to test for the heterogeneity of the association between total calcium intake and colorectal cancer risk by 
densities of tumor-infiltrating T-cell subsets. 
§: Multivariable hazard ratios were adjusted for age (in month), race (Caucasian vs. non-Caucasian), adult BMI (< 25, 25 -< 27.5, 27.5 -< 30, or ≥ 
30 kg/m
2
), smoking (0, 1-10, or > 10 pack-years), history of colorectal cancer in a parent or sibling (yes or no), history of 
sigmoidoscopy/colonoscopy (yes or no), physical activity (< 3, 3-< 27, ≥ 27 MET-hrs/wk), regular aspirin use (yes, no), alcohol 
consumption (0 -< 5, 5 -< 15, or ≥ 15 g/d), energy-adjusted total intake of folate, vitamin D, red meat and processed meat (all in tertiles). 
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